34 results about "Endocrine functions" patented technology

Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

The invention discloses a traditional Chinese medicine composition for preventing and treating premature ovarian failure and application thereof. Belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition comprises gordon euryale seed, agilawood, sandalwood, processed rhizoma pinelliae, rheum officinale, amomum cardamomum, alpinia katsumadai, processed rhizoma arisaematis, processed radix aconiti, asarum, fructus aurantii and fructus piperis longi. The composition follows the compatibility principle of monarch, minister, assistant and guide in traditional Chinese medicine, belongs to a composite traditional Chinese medicine preparation, and needs to regulate the reproductive endocrine function through the synergistic effect of multiple medicinal materials. The traditional Chinese medicine focuses on phlegm-dampness stasis and kidney-yang deficiency type infertility and premature ovarian failure. The prior art purely focuses on tonifying the kidney (such as prepared rehmannia root and dogwood) or activating blood (such as peach kernel and safflower), while the formula disclosed by the invention integrates multiple effects of resolving dampness, warming and dredging, removing stasis, promoting the circulation of qi and the like, and is stronger in pertinence.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for improving ovarian function damage and degeneration and a preparation method thereof. The invention discloses the GnRH agonist effect of dihydromyricetin DMY for the first time, and the affinity of dihydromyricetin DMY to a GnRH receptor and the GnRH agonist effect of dihydromyricetin DMY are verified through in-vitro experiments. Model animal experiments further prove that the dihydromyricetin DMY has a protective effect on ovarian function impairment caused by chemotherapy. Experiments prove that the dihydromyricetin DMY is given while the cyclophosphamide (CTX) is used for chemotherapy, so that the damage of the dihydromyricetin DMY to the ovarian function during chemotherapy can be reduced, and a protection effect is also achieved on the recovery of the ovarian function after drug withdrawal. The protection effect is reflected on the endocrine function and the reserve function of the ovary, and the preserved ovary reserve function can achieve the pregnancy result after chemotherapy is finished, which indicates that the dihydromyricetin DMY also plays the protection effect on the fertility function of the ovary.

Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

The invention relates to a preparation process and a formula for improving female health, and the preparation process comprises the following steps: mixing raw materials such as a plant extract, an amino acid mixture, mineral powder and the like in sequence, emulsifying, carrying out constant-temperature enzyme activation, cooling, carrying out ultraviolet sterilization and the like. The preferable ratio and process parameters ensure the synergistic effect of the components, regulate endocrine, relieve menstrual discomfort and improve the nutrition absorption efficiency. Through a scientific formula and an optimized process, the defects of component matching and efficacy optimization in the prior art are overcome, meanwhile, the health care product has the advantages of being efficient, stable and suitable for industrial production, and an innovative solution is provided for development of female health products.

A hydrogel includes the crosslinked dextran polymer of the invention and / or a hydrogel that further includes biological cells. The hydrogel has a therapeutic use for treating a disorder or disease in a mammal wherein the disorder or disease is due to lack or malfunction of endocrine function of pancreas organ. An implant includes the hydrogel and further includes a ring and a net.

The invention is in the field of medical formulations. Specifically, the invention provides a pharmaceutical composition, the pharmaceutical composition comprises in-vitro regenerated platelets and / or a culture supernatant of the in-vitro regenerated platelets, and the in-vitro regenerated platelets have the following characteristics: the FGF level is significantly increased and / or the VEGF level is significantly increased; the pharmaceutical composition is used for promoting ovarian regeneration, improving ovarian endocrine function, improving ovarian reserve function, and / or improving mouse fertility outcome.

This invention relates to 2-amino-4-methylquinazoline compounds, their preparation methods, uses, and pharmaceutical compositions. Specifically, it provides a compound represented by Formula I, which is a phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor that can be used to prevent and / or treat diseases related to PI3Kδ activity, such as tumors, autoimmune diseases, immunodeficiency diseases, inflammation, kidney diseases, cardiovascular diseases, metabolic / endocrine disorders, or neurological diseases.

This invention belongs to the field of biomedicine, and specifically relates to the application of FeTMPyP in the preparation of drugs to alleviate ovarian toxicity. This application addresses the issue that combined exposure to MC-LR and NaNO₂ significantly induces nitrification stress in mouse ovaries, leading to follicular barrier disruption and ovarian reproductive endocrine dysfunction. FeTMPyP was selected as an intervention agent, which effectively alleviated nitrification stress induced by combined exposure to MC-LR and NaNO₂ in mouse ovaries, and improved sex hormone disorders, estrous cycle irregularities, and follicular atresia caused by the combined exposure to these two toxins. Simultaneously, it restored the fertility of mice, indicating that FeTMPyP intervention can alleviate ovarian toxicity induced by combined exposure to MC-LR and NaNO₂ in mice. This invention can be used to prepare drugs to prevent and treat diseases related to ovarian toxicity caused by environmental toxin exposure in mice, providing a new approach for the early identification and targeted intervention of ovarian-related diseases.

The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and / or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism / endocrine function disorders or neurological diseases.

The present invention discloses a Chinese medicine composition for preventing and treating premature ovarian failure and its application. It belongs to the technical field of traditional Chinese medicine. The Chinese medicine composition of the present invention comprises Euryale ferox, Aquilaria sinensis, Santalum album, processed Pinellia ternata, Rhubarb, White cardamom, Alpinia officinalis, processed Arisaema consanguineum, processed Chuanwu, Asarum sieboldii, Citrus aurantium and Piper longum. The prescription of the present invention follows the principle of "monarch, minister, assistant and envoy" compatibility in traditional Chinese medicine and belongs to a compound Chinese medicine preparation, which needs to regulate reproductive endocrine function through the synergistic effect of multiple medicinal materials. It focuses on infertility and premature ovarian failure caused by phlegm-dampness and blood stasis combined with kidney yang deficiency. The existing technology mostly focuses on simple kidney tonification (such as Rehmannia glutinosa and Cornus officinalis) or blood circulation (such as peach kernel and safflower), while the prescription of the present invention integrates multiple functions such as removing dampness, warming and promoting circulation, purging blood stasis and promoting qi, and is more targeted.

Lighting systems, methods, and devices for protecting human circadian neuroendocrine function during night use are described. Suitable lighting conditions can be provided for a working environment while protecting the circadian neuroendocrine systems of those occupying the illuminated workplace during the night. Lighting systems, methods, and devices can provide substantive attenuation of the pathologic circadian disruption in night workers. Lighting systems, methods, and devices can attenuate the specific bands of light implicated in circadian disruption. LED lighting systems, methods, and devices can provide increased intensity at a different portion of the spectrum than conventional LEDs, providing a useable white light even when unfavorable portions of the wavelength are attenuated by a notch filter. LED lighting systems, methods, and devices can switch between a daytime configuration and a night time configuration, wherein the daytime configuration provides unfiltered light and the night time configuration provides filtered light.

The present application provides a preparation method of ganoderma triterpene and its application in preparing an antidepressant, the prepared ganoderma triterpene has clear material basis, stable component composition and controllable preparation process, the ganoderma triterpene can improve stress-induced abnormal behavior, protect hippocampus and intestinal tissue structure, regulate inflammatory response, neuroendocrine function and various neurotransmitter homeostasis, and realize the synergistic regulation of the intestinal-brain axis function by regulating the intestinal flora structure and its metabolites. The present application provides an implementable technical solution for the application of ganoderma triterpene in functional food or natural antidepressant preparation.

The invention belongs to the technical field of medicines, and particularly relates to a tri-substituted quinazoline compound, a preparation method and application thereof and a pharmaceutical composition. The polysubstituted quinazoline compound is shown as a formula (I), is a PI3K inhibitor, and can be used for preparing medicines for preventing and / or treating diseases related to PI3K activity, such as tumors, autoimmune diseases, kidney diseases, cardiovascular diseases, inflammation, metabolic dysfunction, endocrine dysfunction or nerve diseases. # imgabs0 #

A novel medical use of ingenol HEP14, a dosage form of an HEP14-based drug, and a preparation method for the dosage form. The dosage form of the HEP14-based drug is an HEP14 / PLGA microsphere sustained-release dosage form formed by encapsulating the HEP14-based drug with a polylactic acid-glycolic acid copolymer, and has the functions of high HEP14 drug loading rate, high encapsulation rate, and long-acting HEP14 sustained-release. It has been found for the first time that HEP14 can promote production and autophagy of mitochondria in cells and enhance the function of mitochondria in cells, promote the secretion of antioxidant enzymes and remove reactive oxygen species, promote the growth and viability of ovarian follicle granulosa cells and restore the growth and viability of aging granules, promote the secretion of angiogenic factors, reduce the fibrosis of ovarian tissues, promote the angiogenesis of ovarian tissues, and promote the regeneration of aged ovarian follicles and ovarian endocrine functions, and thus has a good effect of treating and / or preventing related diseases caused by mitochondrial dysfunction, especially the effect of treating age-related ovarian decline.

The invention discloses a Chinese herbal medicine formula for treating diabetes. The Chinese herbal medicine formula comprises the following raw materials in parts by weight: 10g of American ginseng, 35g of Chinese yam, 20g of ganoderma lucidum, 25g of rhizoma polygonati, 25g of pollen and 25g of gynostemma pentaphylla. The formula provided by the invention has a remarkable effect of reducing blood sugar, and American ginseng in the formula can regulate glycometabolism of an organism; the Chinese yam is beneficial to improving the digestive function and the kidney function of the diabetic patient; the lindernia ruellioides can regulate the immune system and enhance the body resistance, and also has a certain regulating effect on blood sugar; the rhizoma polygonati can improve the yin deficiency symptom of a diabetic patient; the pollen can regulate endocrine and promote glycometabolism; gynostemma pentaphyllum has the effects of clearing away heat and toxic materials, relieving cough, clearing away lung-heat, eliminating phlegm, tranquilizing mind by nourishing the heart, tonifying qi and generating essence, and has certain help to reduce blood sugar and blood fat, and the traditional Chinese medicines have a synergistic effect, so that the blood sugar level can be effectively reduced.

This invention discloses a post-natal plant polypeptide compound preparation for regulating endocrine function and nourishing the ovaries, which, by mass percentage, consists of the following components: 60.0%–75.0% purified water, 3.0%–6.0% lactic acid bacteria fermentation lysate, 2.0%–4.0% L-arabinose, 1.5%–3.5% double-petaled red rose extract, 1.0%–3.0% cordyceps extract, 1.0%–2.5% γ-aminobutyric acid, 1.5%–3.0% red ginseng concentrate, 1.0%–2.5% cranberry fruit powder, 0.5%–2.0% turmeric extract, and vitamin C. The ingredients include 0.5%–1.5%, frog polypeptide powder 1.0%–3.0%, carob extract 1.0%–2.5%, roselle extract 0.5%–2.0%, tremella polysaccharide 0.5%–2.0%, and yeast β-glucan 0.5%–2.0%; the sum of the mass percentages of each ingredient is 100%. The ingredients of this invention work synergistically to exert multiple effects such as endocrine regulation, uterine and ovarian care, pelvic floor muscle repair, and skin firming and moisturizing, solving the problems of single efficacy and poor synergy in existing preparations.

The invention relates to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine effective part composition for treating hyperplasia of mammary glands, a traditional Chinese medicine preparation and application. Comprising the following components in parts by weight: 10-25 parts of a centipede rhizome total saponin extract, 10-25 parts of a cucurbit rhizome total terpene extract, 10-25 parts of a star-flower root total terpene extract, 5-10 parts of a radix paeoniae alba total terpene extract, 5-15 parts of a platycodon grandiflorum total flavone extract, 5-10 parts of a paederia scandens total terpene extract, 5-10 parts of a gentiana apiata total flavone extract, 5-10 parts of a bighead atractylodes rhizome total terpene extract and 5-10 parts of a fructus aurantii total flavone extract. 5-10 parts of a common cnidium fruit total coumarin extract; the traditional Chinese medicine preparation comprises the composition and auxiliary materials. The invention also discloses application of the composition in preparation of medicines for treating hyperplasia of mammary glands and breast nodules. The traditional Chinese medicine composition directly acts on a focus part according to a treatment principle of activating blood, soothing the liver, removing stasis and regulating endocrine, and is used for treating hyperplasia of mammary glands and breast nodules in a multi-way synergistic manner.

The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and / or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism / endocrine function disorders or neurological diseases.

The present application relates to a hydrogel for cell therapy. The invention relates to a hydrogel comprising a cross-linked dextran polymer according to the invention, and / or further comprising biological cells. It further relates to the therapeutic use of a hydrogel according to the invention for the treatment of a condition or disease in a mammal, wherein the condition or disease is due to a lack of or dysfunction of the endocrine function of the pancreatic organ, and to an implant comprising a hydrogel according to the invention. It further relates to an implant comprising a hydrogel according to the invention and further comprising a loop and a mesh.

The application discloses application of an HDAC inhibitor MS-275 in preparation of an ovarian function protection drug and belongs to the technical field of biology and pharmacy. The application finds that MS-275 can safely and effectively improve the endocrine function of ovaries, ovarian reserve, fertility and the like of mice in a drug protection group. Therefore, the application proposes that MS-275 can delay ovarian aging, and plays an important role in delaying ovarian aging and / or repairing ovarian damage and / or improving ovarian reserve function and / or reconstructing ovarian function and the like.

The invention discloses application of spermidine in preparation of a preparation for resisting oxidative stress injury of ovarian granular cells, and belongs to the technical field of biological medicines. The content of the invention shows that spermidine can improve the ovarian endocrine function and reproductive capacity of oxidative stress mice, normalize the estrus cycle, relieve oxidative stress, increase ovarian reserve and reduce GC cell apoptosis, and verifies that spermidine indeed has the effect of resisting oxidative stress of ovarian granular cells. A thought is provided for solving the problem of oxidative stress of the ovarian granular cells.

The invention relates to lactobacillus crispatus capable of relieving ovarian function decline and application of the lactobacillus crispatus, and belongs to the technical field of biological medicine. The invention provides a lactobacillus crispatus strain, the preservation number of the lactobacillus crispatus strain is CGMCC No.36731, and the lactobacillus crispatus strain is commercially named as lactobacillus crispatus XA-02D; the strain can improve the level of an anti-aging marker (NAD +) in an ovary of an ovarian function decline model mouse, reverse ovarian atrophy of the ovarian function decline model mouse, reverse estrus cycle disorder of the ovarian function decline model mouse, protect the ovarian reserve function of the ovarian function decline model mouse, and improve the ovarian function decline of the ovarian function decline model mouse. Compared with the prior art, the strain has the advantages of improving endocrine dysfunction of an ovarian function decline model mouse and activating a synthetic pathway of an anti-aging marker in an ovary of the ovarian function decline model mouse, so that the strain can effectively relieve typical symptoms of ovarian function decline and has the functions of treating ovarian reserve hypofunction, premature ovarian insufficiency and premature ovarian failure.

This invention discloses a novel use of M1 (Leonurus glucuronide, ZYZ-488), the main glucuronide conjugate metabolite of leonurine, in the preparation of drugs for preventing and treating endometrial damage and / or intrauterine adhesions caused by mechanical curettage. M1 promotes endometrial regeneration, remodeling, and restoration of endocrine function by increasing serum prostaglandin E2 (PGE2) and / or leukemia inhibitory factor (LIF) levels, while simultaneously restoring serum estradiol (E2) and / or progesterone (P4) levels to normal physiological ranges. It also significantly increases endometrial thickness, the number and regular arrangement of glands, improves stroma density, and enhances tissue morphology remodeling. This invention overcomes the technical bias that Phase II metabolites are typically considered inactivated forms, as well as the thrombotic risks of existing estrogen drugs (EVs) and the strong irritation and insufficient long-term protection of the parent compound SCM-198. It provides a safe, mild, stable, and suitable oral formulation for long-term use, offering a novel and effective drug option for the prevention and treatment of clinical endometrial damage and intrauterine adhesions.

The present application relates to the technical field of functional food, in particular to a sturgeon ovary peptide with endocrine function regulation and a preparation method thereof, which comprises the following steps: taking sturgeon ovary tissue, removing fat and impurities; adding deionized water and sodium ascorbate, homogenizing and vacuum defoaming to obtain a pretreated liquid; adding compound protease to the pretreated liquid for enzymolysis; after the enzymolysis is completed, centrifugal separation is carried out on the supernatant after cooling; the supernatant is separated through an ultrafiltration membrane, and then a low-temperature microwave-assisted oxidation cross-linking reaction is carried out, and hydrogen peroxide and a mixture of naringin / soy isoflavones are added; finally, vacuum freeze-drying is carried out to obtain the sturgeon ovary peptide with endocrine function regulation. In the present application, the microwave-assisted oxidation cross-linking and the incorporation of naringin and soy isoflavones significantly reduce the oxidation loss in the high-temperature drying process, further stabilize the active conformation and enhance the binding affinity to the estrogen receptor.

The present invention belongs to the field of medical preparations. Specifically, the present invention provides a pharmaceutical composition comprising in vitro regenerated platelets and / or culture supernatant of the in vitro regenerated platelets, wherein the in vitro regenerated platelets exhibit the following characteristics: significantly increased levels of FGF and / or significantly increased levels of VEGF; the pharmaceutical composition is used to promote ovarian regeneration, improve ovarian endocrine function, improve ovarian reserve function, and / or improve reproductive outcomes in mice.

This invention discloses an acupoint electroacupuncture microcurrent combination therapy device for regulating endocrine function, belonging to the technical field of acupoint electroacupuncture therapy devices. It includes a therapy device housing with a microcurrent circuit inside; a switch and multiple knobs, all located on the panel of the therapy device housing, the switch controlling the on / off state of the therapy device; multiple electroacupuncture connecting wires, arranged in an equidistant array on the side wall of the therapy device housing, the intensity of the microcurrent released by the connecting wires controlled by the knobs; and an adsorption component and a limiting component. The adsorption component ensures the therapy device can be quickly and stably fixed on a flat contact surface, providing good adsorption and sealing, and preventing displacement, thus preventing the electroacupuncture from detaching from the acupoint during treatment and ensuring the continuity of treatment. The limiting component precisely limits the electroacupuncture connecting wires, preventing them from being pulled off, and effectively protecting the connection points, avoiding any impact on the treatment effect due to loose connecting wires.

The invention relates to the technical field of biological medicines, in particular to application of an MT-CO2 gene inhibitor in preparation of a medicine for treating organ injury diseases. Experimental evidences show that MT-CO2 mRNA can be actively secreted to extracellular gaps and whole body circulatory systems, is widely distributed among tissues and organs and plays a unique regulation function. This discovery establishes the status of mitochondria as a novel endocrine organelle, which endows it with the ability to generate and release hereditary endocrine media into systemic circulation, thereby redefining all mitochondrial-containing cells as potential endocrine cells. The endocrine-like function of the mRNA outside the mitochondria reveals an important mechanism of interorgan communication and cell reprogramming, and opens up a brand new view for endocrine biology research. MT-CO2 is associated with various organ injury diseases, and expression of DYNC2H1 is interfered by an MT-CO2 gene inhibitor, so that the organ injury diseases are treated. The invention opens up a brand new target for treatment of various human diseases.

The invention provides strontium-rich concentrated bone soup as well as a preparation method and application thereof, and belongs to the technical field of health-care food. The invention provides a strontium-rich concentrated bone soup. The strontium-rich concentrated bone soup comprises the following raw materials: old hens, pig bones, natural mineral water rich in strontium element and a Chinese herbal medicine composition. In the invention, the old hen can bring delicious taste to the strontium-rich concentrated bone soup and also has the effects of benefiting qi and nourishing blood; the pig bones can supplement nutrient substances and energy required by the human body, enhance the immunity of the human body, regulate the endocrine function, strengthen the physique and improve the virus resistance of the human body. In addition, the natural mineral water rich in strontium element is used as the basis of decoction, and the strontium element can be better provided for the human body. In addition, the Chinese herbal medicine composition can improve the health-care effect of the strontium-enriched concentrated bone soup. The strontium-rich concentrated bone soup disclosed by the invention meets the requirements of modern people on healthy diet.

The invention discloses application of berberine (hereinafter referred to as BBR) in preparation of a medicine for preventing and / or delaying ovarian physiological senescence, and belongs to the technical field of biological medicine. The invention aims to provide a medicine application scheme capable of effectively delaying ovarian senescence and improving ovarian functions. Animal experiment research finds that the BBR can significantly increase the number and quality of oocytes in physiologically aged mice and promote the increase of the levels of anti-mullerian hormone and estradiol, so that the ovarian endocrine function is improved. The invention has the following beneficial effects: BBR can improve ovarian function at animal level and delay ovarian physiologic aging, and provides a new idea and technical basis for development of related drugs.